what are the risks of glp-1 Peptide/GLP-1 Complications: 11 Hidden and Side Effects You Must Know The promise and peril of

Description

Clinical trials (ten studies, 419 participants) using doses from 400 mg to 10 g over 21 days to 20 months show consistent reductions in fasting glucose, post-meal glucose, and HbA1c. In diabetic animal studies, gymnema increased proglucagon gene expression (a precursor for GLP-1) and insulin gene activity, suggesting it may help amplify endogenous GLP-1 production

A new report supports lower GLP-1 levels related to gut microbiome dysregulation @Cell_Metabolism

Adults focused on digestive wellness and microbial diversity

Patients with multiple comorbidities, especially those with limited treatment options, are significantly more likely to initiate GLP1 therapy

Awareness of the latest AOM molecules and brands is lowest among GPs/IMs IQVIAs primary research was conducted shortly after the 3rd October announcement of the NHS England/Lilly deal for the phased launch of Mounjaro for obesity